News
"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at ...
Advisers to the U.S. Food and Drug Administration will discuss recommendations for updated COVID-19 vaccines ahead of the ...
The U.S. Food and Drug Administration plans to require new clinical trials for approval of annual COVID-19 boosters for ...
Top officials in the Trump administration on Tuesday announced they will limit the approval of new COVID-19 vaccines to ...
In an editorial article published in the New England Journal of Medicine, Dr. Vinay Prasad, the newly appointed head of the ...
The agency will narrow its approval for updated coronavirus vaccines, marking a significant shift in the agency’s approach to ...
Explore more
The vaccine, Nuvaxovid, is the third coronavirus shot to gain full approval, joining vaccines from Pfizer and Moderna. It has ...
The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine, but with unusual ...
Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.
The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.
Novavax makes the nation’s only traditional protein-based coronavirus vaccine – and until now it had emergency authorization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results